Cyberounds Logo
September 28, 2020 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Anti-EGFR Therapy: Incidence, Pathology and Management of Associated Side Effects
CME credit is no longer available for this conference.
Sunil Babu, M.D., Michael Liu, M.D., and Robert G. Lerner, M.D.

Dr. Babu is Fellow in Hematology/Oncology at New York Medical College/Westchester Medical Center, Valhalla, NY, and Dr. Liu is Resident in Internal Medicine at Cabrini Medical Center, New York, NY.

Within the past 12 months, Dr.Babu and Dr. Liu report no commercial conflicts of interest. Dr. Lerner reports research support from Boehringer-Ingelheim, Sanofi-Aventis and Bayer and is on the Speakers Bureau for Sanofi-Aventis, GlaxoSmithKline and Eisai.

Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose.

This activity is made possible by an unrestricted educational grant from Bristol Myers Squibb

Release Date: 06/05/2007
Termination Date: 06/05/2010

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Describe the common side effects associated with EGFR inhibition
  • Discuss the correlation between dermatologic side effects of EGFR inhibition and response to therapy
  • Discuss the possible mechanisms of dermatologic side effects of EGFR inhibitor therapy
  • Discuss the common principles of management of dermatologic and non-dermatologic side effects.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Please click below to accept the terms of this CME activity